New insider activity at Crispr Therapeutics AG ( (CRSP) ) has taken place on March 1, 2025.
John Greene, the Executive Vice President and Chief Financial Officer of Crispr Therapeutics AG, has made a significant investment by purchasing 7,000 shares of the company’s stock. This transaction is valued at $313,880, highlighting his confidence in the company’s future prospects.
More about Crispr Therapeutics AG
YTD Price Performance: 5.29%
Average Trading Volume: 2,187,361
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.74B